Gestational Diabetes Market
Report ID: SQMIG35I3127
Report ID: SQMIG35I3127
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I3127 |
Region:
Global |
Published Date: July, 2026
Pages:
157
|Tables:
121
|Figures:
77
Global Gestational Diabetes Market size was valued at USD 9.21 Billion in 2024 and is poised to grow from USD 10.05 Billion in 2025 to USD 20.16 Billion by 2033, growing at a CAGR of 9.1% during the forecast period (2026-2033).
Gestational diabetes mellitus (GDM) is a fast‑growing segment of the diabetes care market, defined by glucose intolerance first detected during pregnancy. Its importance stems from the combined risk to mothers and infants, driving heightened clinical focus and investment. Historically fragmented, the market has expanded as obesity, delayed childbearing, and shifting ethnic demographics raise the at‑risk pool.
Beyond the demographic surge, digital health platforms have become a pivotal growth engine for the global gestational diabetes market. Data sharing lets obstetricians adjust insulin regimens promptly, reducing adverse birth outcomes and encouraging wider tele‑monitoring adoption. Companies such as Abbott and Dexcom introduced pregnancy‑specific continuous glucose monitoring models, showing how technology attracts insurer reimbursement for cost‑saving solutions. Consequently, hospitals invest in remote‑care infrastructure, creating a cascade where increased device uptake fuels software development, analytics ventures, and comprehensive education programs. This ecosystem expands revenue streams and drives public policy shifts that embed gestational diabetes management into clinical standard routine prenatal care.
How is AI and IoT integration transforming the gestational diabetes market?
AI and IoT are reshaping gestational diabetes care by linking continuous glucose monitors, wearable sensors, and predictive analytics into unified platforms. Real‑time data streams enable clinicians to spot rising blood‑sugar trends before they become problematic, while algorithms suggest personalized diet and medication adjustments. This integration reduces clinic visits, empowers pregnant women with actionable insights, and supports tighter glycemic control, which is critical for maternal and fetal health. The market is expanding as these technologies become more affordable and as healthcare systems prioritize remote monitoring solutions. Together, AI‑driven decision support and IoT connectivity are driving a shift toward proactive, data‑rich management of gestational diabetes.
In August 2025, a leading medical‑device company launched an AI‑enhanced smart glucose monitor, streamlining data collection and analysis, and accelerating adoption of connected care in the gestational diabetes market.
Market snapshot - (2026-2033)
Global Market Size
USD 9.21 Billion
Largest Segment
Oral Glucose Tolerance Test (OGTT)
Fastest Growth
Hemoglobin A1c (HbA1c) Test
Growth Rate
9.1% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global gestational diabetes market is segmented by diagnosis type, treatment type, end user, distribution channel and region. Based on diagnosis type, the market is segmented into Oral Glucose Tolerance Test (OGTT), Fasting Blood Sugar Test, Random Blood Sugar Test and Hemoglobin A1c (HbA1c) Test. Based on treatment type, the market is segmented into Dietary Changes & Lifestyle Modification, Insulin Therapy, Oral Medications, Continuous Glucose Monitoring (CGM) and Physical Activity Programs. Based on end user, the market is segmented into Hospitals, Diagnostic Laboratories, Homecare Settings and Maternity Clinics. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Oral glucose tolerance test segment dominates with large gestational diabetes market share because it remains the clinical gold standard for confirming gestational diabetes, offering comprehensive glucose profiling across fasting and post‑load periods. Its ability to capture subtle dysglycemia drives clinician confidence, leading to widespread adoption in prenatal screening protocols, and integrates seamlessly with electronic health records, facilitating longitudinal monitoring and research initiatives for both clinicians and patients.
As per gestational diabetes market outlook, Hemoglobin A1c test segment is witnessing the strongest growth momentum as point‑of‑care devices become more accurate and convenient for pregnant women. The reduced need for fasting and the ability to monitor long‑term glycemic trends are spurring clinician interest, expanding its role beyond confirmation to ongoing management, thereby opening new market opportunities.
As per gestational diabetes market forecast, maternity clinics segment dominates because they serve as the primary touchpoint for prenatal care, enabling early identification and coordinated management of gestational diabetes within the obstetric workflow. Their integrated access to obstetricians, dietitians, and laboratory services fosters comprehensive patient education and timely interventions, reinforcing adherence to clinical guidelines. This central role consolidates patient flow and drives consistent demand for diagnostic and therapeutic solutions within the gestational diabetes market.
Meanwhile, homecare settings segment is emerging as the key high‑growth segment as monitoring technologies and telehealth platforms gain acceptance among pregnant patients. The convenience of at‑home glucose testing and coaching reduces clinic visits, enhancing patient empowerment and adherence. This shift creates revenue streams for device manufacturers and expands market reach beyond traditional clinical environments.
To get detailed segments analysis, Request a Free Sample Report
North America leverages a mature healthcare ecosystem, extensive research networks, and high adoption of advanced diagnostic technologies that collectively sustain its leadership. The region benefits from well‑established clinical guidelines, strong reimbursement frameworks, and a culture of proactive maternal health management. Collaborative partnerships between academic institutions, pharmaceutical firms, and device manufacturers accelerate innovation and streamline product launch cycles. Additionally, a concerted focus on patient education and comprehensive prenatal screening programs reinforces market depth and reinforces North America’s position as a benchmark for quality care.
As per gestational diabetes market regional outlook, United States is reinforced by a pervasive culture of early detection and integrated care pathways, supported by leading academic medical centers and a robust pipeline of therapeutic developments. The presence of multiple specialist networks and coordinated insurance coverage drives consistent patient access, while ongoing clinical research fuels continuous refinement of treatment protocols and technology integration.
As per gestational diabetes market regional forecast, Canada thrives on a publicly funded health system that prioritizes universal access to prenatal screening and diabetes management resources. Collaborative initiatives between government agencies, research institutions, and industry stakeholders promote the adoption of evidence‑based practices and facilitate the introduction of innovative monitoring devices, ensuring comprehensive support for expectant mothers nationwide.
Europe’s expansion is propelled by harmonized regulatory standards, a strong emphasis on preventive health, and widespread implementation of national screening programs. The region’s interconnected research landscape encourages cross‑border collaborations, accelerating the development of novel therapeutics and digital health solutions. Growing awareness of maternal metabolic health, combined with supportive reimbursement policies and an ageing maternal demographic, further stimulates demand. These factors collectively enhance market dynamism and position Europe as a hub for cutting‑edge gestational diabetes care.
Germany benefits from a highly organized healthcare delivery model and deep integration of clinical guidelines within routine obstetric practice. Strong university hospital networks drive continuous clinical research, while public insurance schemes ensure broad patient coverage for both pharmacologic and lifestyle interventions, fostering comprehensive disease management.
United Kingdom is accelerated by aggressive adoption of digital health platforms and an expanding telemedicine infrastructure that enhances patient monitoring and clinician collaboration. National health services promote standardized screening protocols, and policy initiatives emphasize early intervention, creating a fertile environment for rapid market growth.
France is emerging through concerted efforts to integrate preventive screening within primary care and to increase public awareness of maternal health risks. Collaborative programs between research institutes and industry promote the translation of innovative therapies into clinical practice, while evolving reimbursement pathways support broader access to emerging treatment options.
Asia Pacific is advancing its market stance by leveraging rapid urbanization, expanding middle‑class populations, and heightened focus on maternal health outcomes. Regional governments are modernizing healthcare infrastructure, investing in diagnostic capabilities, and fostering public‑private partnerships that accelerate technology transfer. Growing clinical research capacity and increasing adoption of mobile health solutions enhance patient engagement and enable scalable management strategies, positioning the region as an emerging leader in gestational diabetes care.
Japan is bolstered by a sophisticated healthcare system that emphasizes early prenatal assessment and seamless integration of advanced monitoring devices. Strong emphasis on evidence‑based practice and collaboration between medical societies and industry drives continuous improvement of therapeutic options and patient education initiatives.
South Korea gains momentum through aggressive digital health adoption and a proactive governmental stance on maternal wellness. Integrated electronic health records and widespread use of mobile applications improve real‑time glucose monitoring, while research collaborations expedite the introduction of novel pharmacologic agents into clinical practice.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Maternal Awareness
Advances In Continuous Monitoring
Limited Reimbursement Policies
Lack Of Standardized Screening
Request Free Customization of this report to help us to meet your business objectives.
The gestational diabetes industry is shaped by intense competition among pharmaceutical and med‑tech firms that are accelerating product pipelines through strategic acquisitions, joint ventures with digital‑health platforms, and the integration of continuous glucose monitoring technologies into prenatal care programs, exemplified by recent partnership deals that combine insulin therapies with AI‑driven patient management tools.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the gestational diabetes market growth is propelled primarily by rising maternal awareness, which fuels demand for early screening and personalized care, while advances in continuous monitoring represent a second strong driver by enabling real‑time data and remote management. The oral glucose tolerance test remains the dominating segment because it is the clinical gold standard for diagnosis, and North America leads the market due to its mature healthcare system, strong reimbursement frameworks and high technology adoption. However, limited reimbursement policies act as a significant restraint, slowing the uptake of innovative monitoring devices and digital‑health solutions across many regions. The global gestational diabetes market trend driven by the rising prevalence of maternal obesity, delayed pregnancies, sedentary lifestyles, and increasing rates of diabetes worldwide.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 9.21 Billion |
| Market size value in 2033 | USD 20.16 Billion |
| Growth Rate | 9.1% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Gestational Diabetes Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Gestational Diabetes Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Gestational Diabetes Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Gestational Diabetes Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Gestational Diabetes Market size was valued at USD 9.21 Billion in 2024 and is poised to grow from USD 10.05 Billion in 2025 to USD 20.16 Billion by 2033, growing at a CAGR of 9.1% during the forecast period (2026-2033).
The gestational diabetes market is shaped by intense competition among pharmaceutical and med‑tech firms that are accelerating product pipelines through strategic acquisitions, joint ventures with digital‑health platforms, and the integration of continuous glucose monitoring technologies into prenatal care programs, exemplified by recent partnership deals that combine insulin therapies with AI‑driven patient management tools. 'Novo Nordisk A/S', 'Eli Lilly and Company', 'Sanofi S.A.', 'Abbott Laboratories', 'F. Hoffmann-La Roche Ltd.', 'Johnson & Johnson Services, Inc.', 'Becton Dickinson and Company', 'Medtronic PLC', 'Dexcom, Inc.', 'Ascensia Diabetes Care Holdings AG', 'Merck & Co., Inc.', 'AstraZeneca PLC', 'Boehringer Ingelheim GmbH', 'Baxter International Inc.', 'OmniPod (Insulet Corporation)', 'B. Braun Melsungen AG', 'Tandem Diabetes Care, Inc.', 'Global Diabetes Supply', 'Edgepark Medical Supplies', 'National Diabetes Supplies'
Increasing maternal awareness drives demand for gestational diabetes screening and management solutions, as expectant mothers become more proactive in seeking prenatal care. Healthcare providers respond by offering comprehensive testing protocols and personalized treatment plans, which in turn expands the market for diagnostic devices, glucose monitoring systems, and therapeutic services. This heightened engagement also encourages adoption of digital health platforms that facilitate remote monitoring, fostering a broader ecosystem that supports sustained market growth through improved patient outcomes and satisfaction and long-term sustainability.
Personalized Nutrition Integration: Healthcare providers are increasingly incorporating individualized dietary plans, guided by continuous glucose monitoring data, into gestational diabetes management. This approach enables clinicians to tailor macronutrient composition and meal timing to each patient’s metabolic response, improving glycemic control while supporting fetal growth. As nutrition tech platforms mature, they offer real‑time feedback and predictive insights, fostering patient engagement and adherence. Consequently, providers view nutrition‑focused strategies as core differentiators in delivering comprehensive, outcomes‑driven care that align with clinical guidelines and maternal health goals.
Why does North America Dominate the Global Gestational Diabetes Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
